News Quantified

GRTX – galera therapeutics inc (US:NASDAQ)

Stock Stats

News Stats


All News	{{AllNewsCount}}
News Wires	{{NewsWiresCount}}
Media Monitoring	{{MoreOverCount}}
SEC Edgar Filings	{{SecEdgarFilingsCount}}
Upgrades	{{UpgradesCount}}
Downgrades	{{DowngradesCount}}
Initiated	{{InitiatesCount}}
Reiterated	{{ReiteratesCount}}
Last Earnings	{{LastEarnings}}
Last Earnings EPS	{{LastEps}}
Next Earnings	{{NextEarnings}}

Order Stats

Sub-Penny
{{SubPennyStr}}
Odd Lot
{{OddLotStr}}
Avg. bid-ask spread

{{GetAvgBidAskSpreadForScale}}
Avg. bid / ask size
{{GetAvgBidSizeForScale}} {{GetAvgAskSizeForScale}}

Shares at ask / bid
{{SharesAtAsk_AMP_Str}} {{SharesAtBid_AMP_Str}}
Off exchange
{{OffExchange}}

News

Form NT 10-Q Galera Therapeutics, For: Sep 30

Form 8-K Galera Therapeutics, For: Oct 17

Form 25-NSE Galera Therapeutics, Filed by: Nasdaq Stock Market LLC

Form 8-K Galera Therapeutics, For: Aug 31

Form DEF 14A Galera Therapeutics, For: Oct 17

Top News Decliners

4/30 Galera Therapeutics Announces Presentation of Avasopasem Manganese Data at ASCO 2020 Virtual Scientific Program -9.6%

11/14 Form 4 Galera Therapeutics, For: Nov 12 Filed by: Clarus IV-D, L.P. -9.3%

2/24 Galera Therapeutics Announces Presentation of Avasopasem Manganese (GC4419) Two-Year Tumor Outcomes Data at 2020 Multidisciplinary Head and Neck Cancers Symposium -7.4%

12/2 Galera Therapeutics (NASDAQ: GRTX) is now covered by analysts at BTIG Research. They set a "buy" rating and a $30.00 price target on the stock. -6.0%

4/30 Galera Therapeutics (NASDAQ: GRTX) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $14.00 price target on the stock. -5.2%

4/22 Galera Therapeutics (NASDAQ: GRTX) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $14.00 price target on the stock. -5.1%

12/10 Form 10-Q Galera Therapeutics, For: Sep 30 -5.0%

11/6 Galera Therapeutics Announces Pricing of Initial Public Offering -4.0%

1/7 Galera Therapeutics Announces Dosing of First Patient in Phase 2a Clinical Trial of Avasopasem Manganese (GC4419) in Second Indication -3.5%

3/10 Q4/2019 12/31/2019 EPS -1.310 ZacksConsensus N/A ActVsEst N/A - N/A -2.5%

Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies

If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.

Click Here To Register For The Live Online Workshop

In short, News Quantified specializes in matching financial news with market data. We've analyzed 10s of millions of news events and know exactly which ones have an outsized impact on stock prices. So every single time a news item is released we know exactly what the average effect will be on a particular stock.

52 Week High	{{GetCompanyStockInfo.Week52HighValue}} {{GetCompanyStockInfo.Week52HighDate}}
52 Week Low	{{GetCompanyStockInfo.Week52LowValue}} {{GetCompanyStockInfo.Week52LowDate}}

Today’s Volatility	{{VolatilityStr}}
20 Day Volatility	{{Volatility20Str}}

Open	{{GetCompanyStockInfo.Open}}
Prior Close	{{GetCompanyStockInfo.PriorCloseValue}} {{GetCompanyStockInfo.PriorCloseDate}}